HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2009 FDA Globalization Act Scratches Fees For Cosmetics, “Unanticipated” AEs

This article was originally published in The Rose Sheet

Executive Summary

The latest version of the FDA Globalization Act includes a number of changes beneficial to small cosmetic firms; however, the draft legislation still presents some overly burdensome requirements, according to Indie Beauty Network founder and CEO Donna Maria Coles Johnson, Esq

You may also be interested in...



Council-Approved Cosmetics Safety Bill Launches

Rep. Leonard Lance, R-N.J., introduces the Cosmetic Safety Amendments Act of 2012, with “the full support” of the Personal Care Products Council. Bill would not require manufacturers to substantiate product safety prior to market or pay user fees, but it does include registration, ingredient disclosure and adverse-event reporting requirements and proposes a significant increase in FDA’s oversight role.

FDA, Industry To Testify At House Cosmetics Hearing

A March 27 hearing titled “Examining the Current State of Cosmetics” will likely focus more on the future of cosmetics regulation in the U.S. CFSAN director Michael Landa is slated to testify, as are representatives from the Personal Care Products Council and small businesses.

Council Backs Rival FDA Cosmetics Legislation In Wake Of SCA

Legislators may soon be considering two rival bills aimed at overhauling regulation of the cosmetics industry – the Safe Cosmetics Act of 2011 and separate legislation backed by the Personal Care Products Council.

Related Content

UsernamePublicRestriction

Register

RS016047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel